教育 来源:南财快讯 时间:2023-06-13 13:01:27
(相关资料图)
南方财经6月13日电,四环医药公告,集团旗下非全资附属公司惠升生物研发的司美格鲁肽注射液用于治疗2型糖尿病的临床试验申请获国家药监局受理,这是惠升生物提交临床实验申请的首个胰高血糖素样肽-1(GLP-1)类似物。
标签:
上一篇:湖北十堰茅箭区:“一老一小”绘就“朝夕美好”温暖画卷|全球热门
下一篇:最后一页
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
22-09-30
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13
23-06-13